MCL Clinical Trials

1230 trials from ClinicalTrials.gov. Recruiting trials shown first.

Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

NCT05025423·PHASE2·Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·7 enrolled

Venetoclax Oral Tablet [Venclexta]

Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma

NCT05486013·Peking University Third Hospital·30 enrolled

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

NCT05360238·PHASE1 / PHASE2·Mustang Bio·20 enrolled

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

NCT05144347·PHASE1·Exelixis·2 enrolled

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

NCT05107856·PHASE1·Prelude Therapeutics·21 enrolled

PRT1419AzacitidineVenetoclax

A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT04849715·PHASE3·Incyte Corporation

parsaclisibrituximabbendamustinePlacebo

Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy

NCT05064787·NA·Pack Health·45 enrolled

Digital Health Coaching

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

NCT05176691·PHASE1·Hutchmed

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

NCT04903197·PHASE1·Novartis Pharmaceuticals·18 enrolled

VAY736lenalidomide

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

NCT05155215·PHASE1 / PHASE2·Beijing Immunochina Medical Science & Technology Co., Ltd.·68 enrolled

IM19 CAR-T cellsCyclophosphamideFludarabine

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

NCT05051891·PHASE3·Beijing InnoCare Pharma Tech Co., Ltd.·3 enrolled

Orelabrutinib and R-CHOPR-CHOP

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

NCT04599634·PHASE1·National Cancer Institute (NCI)·11 enrolled

ObinutuzumabVenetoclaxMagrolimabAcetaminophenDiphenhydramine+7 more

Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

NCT04990778·PHASE2·M.D. Anderson Cancer Center

EprenetapoptVenetoclax

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

NCT05003141·PHASE1·Qilu Puget Sound Biotherapeutics (dba Sound Biologics)·110 enrolled

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05008055·PHASE2·AstraZeneca·30 enrolled

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

NCT05076097·PHASE2·Tianjin Medical University Cancer Institute and Hospital·29 enrolled

Orelabrutinib in in combination of rituximab and lenalidomide(OLR)

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

NCT05645744·Mustang Bio·3 enrolled

Prior MB-102 CAR-T cell investigational product.Prior MB-106 CAR-T cell investigational product.

Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

NCT05020392·PHASE3·Union Hospital, Tongji Medical College, Huazhong University of Science and Technology·24 enrolled

BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 CellsFludarabine-based chemotherapy + CAR-T-CD19 Cells

Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)

NCT04692155·PHASE1 / PHASE2·University of Alabama at Birmingham·1 enrolled

UblituximabUmbralisib

CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL

NCT04995536·PHASE1·City of Hope Medical Center

CpG-STAT3 siRNA CAS3/SS3Radiation Therapy

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

NCT04930536·PHASE4·AstraZeneca·103 enrolled

Acalabrutinib capsule

B-cell Chronic Lymphoid Malignancies Markers

NCT04952974·University Hospital, Strasbourg, France·420 enrolled

Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma

NCT04918940·NA·Centre Henri Becquerel·20 enrolled

Determination of COVID-19 vacciantion efficacy

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

NCT04763083·PHASE1·NovalGen Ltd.·90 enrolled

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

NCT04849416·PHASE2·Eli Lilly and Company·87 enrolled

Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers

NCT04804254·PHASE1·AbbVie·5 enrolled

ABBV-623ABBV-992

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

NCT04880434·PHASE2·Kite, A Gilead Company·95 enrolled

FludarabineCyclophosphamideBrexucabtagene autoleucel

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

NCT05097443·PHASE3·Shandong Provincial Hospital·130 enrolled

Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT04659044·PHASE2·Academic and Community Cancer Research United·3 enrolled

Polatuzumab VedotinRituximabRituximab and Hyaluronidase HumanVenetoclax

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

NCT04703686·PHASE2·The Lymphoma Academic Research Organisation·67 enrolled

ObinutuzumabRO7082859

← PreviousPage 9 of 41Next →